The scale of the problem is expanding rapidly. As cellular therapies and B-cell-depleting agents become standard care for hematologic malignancies, the number of patients with prolonged hypogammaglobulinemia, meaning abnormally low levels of immunoglobulin G, is expected to rise substantially. These patients suffer recurrent bacterial infections, frequent hospitalizations and a marked decline in health-related quality of life. The immune dysfunction is not uniform: B-cell-depleting drugs primarily damage humoral immunity, while stem cell transplantation and CAR-T therapy can produce broader defects that also impair cellular immune defenses and delay immune reconstitution for months or even years. Because diagnostic criteria developed for primary antibody deficiencies do not translate cleanly to these acquired conditions, clinicians must tailor immunoglobulin replacement to each patient’s infection history, immune status and treatment regimen.

The evidence that replacement therapy works is robust. Real-world data and clinical studies consistently show substantial reductions in infections, emergency department visits and hospital admissions once therapy begins. In the Ontario Immunoglobulin Treatment Case Registry, treatment was associated with an 82.6 percent reduction in annual infections, an 84.6 percent reduction in emergency department visits and an 83.3 percent reduction in hospitalizations. A Japanese retrospective cohort of patients with hematologic malignancy-associated hypogammaglobulinemia found that 20 percent subcutaneous immunoglobulin cut infection rates from 3.67 to 1.32 infections per patient-year. Post-marketing data for the subcutaneous product IgPro20 showed similar reductions in infections and serious bacterial events. Randomized trials and consensus guidelines support both routes for infection prevention in chronic lymphocytic leukemia, lymphoma and post-transplant populations.

The two delivery routes differ fundamentally in their pharmacokinetic behavior. Intravenous immunoglobulin is typically given every three to four weeks in a hospital or infusion center, producing a sharp peak in serum IgG followed by a gradual decline toward a trough before the next infusion. Subcutaneous immunoglobulin, by contrast, is administered more frequently, often weekly or biweekly, and sometimes monthly with facilitated formulations, yielding near-steady-state IgG concentrations with minimal peak-to-trough fluctuation. This smoother exposure profile matters clinically, because trough levels are a central pharmacokinetic goal of long-term management. Notably, a retrospective comparison of 131 patients with secondary antibody deficiency and 102 with primary antibody deficiency found that the secondary group achieved comparable reductions in infection burden despite receiving lower doses and reaching lower steady-state IgG trough concentrations, suggesting that dosing requirements differ between the two populations.

Safety profiles also diverge in clinically meaningful ways. Intravenous immunoglobulin carries a higher incidence of systemic adverse reactions, including headache, fever, nausea, thromboembolic events, aseptic meningitis, hemolysis and, less commonly, renal dysfunction or anaphylaxis. Systemic reactions occur in roughly 20 to 50 percent of patients and in 5 to 15 percent of infusions, although most are mild to moderate. Subcutaneous administration produces far fewer systemic events but more frequent local injection-site reactions such as erythema, swelling and rash, which are typically mild and self-limited. Facilitated subcutaneous immunoglobulin, which includes an added enzyme that allows larger volumes to be infused, may further improve tolerability while reducing hospital burden, according to emerging evidence reviewed by the authors.

Beyond infection control, the review highlights patient-reported outcomes as an increasingly important dimension of treatment success. Real-world studies show that subcutaneous therapy is associated with greater treatment convenience, improved autonomy and better quality-of-life scores, largely because patients can self-administer at home rather than traveling to infusion centers. Patients who switch from intravenous to subcutaneous treatment frequently report higher satisfaction and a reduced treatment burden. These gains in daily living are not merely cosmetic: they translate into measurable differences in how immunocompromised cancer survivors experience long-term supportive care.

Health economics reinforce the case for the subcutaneous route. A ten-year cost-utility analysis comparing hospital-based intravenous therapy with home-based subcutaneous therapy found that the subcutaneous approach yielded more quality-adjusted life years, 3.51 versus 3.07, at lower cumulative healthcare cost, making it the dominant strategy from a healthcare system perspective. Home-based administration reduces infusion-center utilization and hospital visits while maintaining clinical effectiveness, and registry data demonstrate durable treatment persistence during long-term subcutaneous therapy in routine practice. As global demand for plasma-derived immunoglobulin continues to climb, the review argues that responsible stewardship of this finite resource requires evidence-informed patient selection, periodic reassessment and timely discontinuation when immune recovery makes replacement unnecessary.

Guidance from major international bodies, including the American Academy of Allergy, Asthma, and Immunology, the British Committee for Standards in Hematology, the National Comprehensive Cancer Network and the European Society for Immunodeficiencies, supports either route for patients with documented hypogammaglobulinemia and recurrent or severe infections. The AAAAI recommends an individualized intravenous dosing range of 0.4 to 0.8 grams per kilogram every 28 days when clinically indicated. In practice, therapy is generally considered for patients with chronic lymphocytic leukemia or multiple myeloma whose IgG levels fall below roughly 400 to 500 milligrams per deciliter and who experience recurrent or severe infections despite appropriate antimicrobial management. Inadequate vaccine responses to diphtheria, tetanus or pneumococcal antigens can further support initiation in selected patients. For stem cell transplant recipients, routine prophylactic intravenous immunoglobulin is not recommended, but either route may be considered when IgG remains below 400 milligrams per deciliter with recurrent or severe infections. After CAR-T therapy, baseline immune assessment and individualized replacement strategies are increasingly advised.

The review emphasizes that there is no universally accepted IgG trough target for this population. Decisions to start, continue, modify or stop therapy should integrate serum IgG concentrations with infection history, underlying disease activity, ongoing immunosuppression and evidence of B-cell reconstitution rather than relying on a single numeric threshold. Monitoring should track infection frequency and severity, adverse events, treatment tolerability and, following B-cell-directed therapy, peripheral B-cell recovery assessed by flow cytometry when appropriate. Patients who remain infection-free and show immune recovery may interrupt or discontinue therapy, with reinitiation if infections recur, although validated biomarker thresholds for stopping treatment have not been established. The primary objective, the authors stress, is prevention of recurrent and severe infections, not achievement of a universal serum IgG number.

Significant gaps remain. Comparative prospective data on subcutaneous versus intravenous therapy in hematologic malignancy populations, particularly among CAR-T and transplant recipients, are scarce, and evidence on survival benefits is limited because most studies were not powered to detect mortality differences. Replacement therapy also addresses only humoral deficiency and cannot correct the broader cellular immune dysfunction that follows transplantation or CAR-T treatment. Several ongoing trials, including registries of facilitated subcutaneous immunoglobulin in multiple myeloma and a dedicated study of immunoglobulin for hypogammaglobulinemia after CAR-T therapy, should help refine dosing, monitoring and discontinuation criteria. For now, the message for clinicians is clear: both routes work, but for patients facing years of antibody replacement, the steadier pharmacokinetics, fewer systemic reactions and home-based convenience of the subcutaneous route make it an increasingly attractive first choice.

Subject of Research: Immunoglobulin replacement therapy via subcutaneous and intravenous routes for secondary immunodeficiency in hematologic malignancy patients

Article Title: Immunoglobulin replacement therapy in hematologic malignancy–associated secondary immunodeficiency: roles of SCIG and IVIG

Article References: Seaquist, E., Majapuro-Hirvonen, A., Van Wagoner, R., & Rutland, B. (2026). Immunoglobulin replacement therapy in hematologic malignancy–associated secondary immunodeficiency: roles of SCIG and IVIG. Frontiers in Hematology, 5, Article 1904290. https://doi.org/10.3389/frhem.2026.1904290

Image Credits: AI Generated

DOI: 10.3389/frhem.2026.1904290

Keywords: immunoglobulin replacement therapy, secondary immunodeficiency, hematologic malignancies, SCIG, IVIG, CAR-T therapy, hypogammaglobulinemia, immune reconstitution, infection prevention, pharmacokinetics, patient-reported outcomes, healthcare cost-effectiveness